What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development? A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment.
A customer sought to increase the titer of a molecule that had proven difficult to express, with a titer insufficient for clinical studies. Learn how our strategy allowed to increase the titer nearly 4-fold after generation of stable pools.
Fields indicated by a * are mandatory.